RALEIGH, N.C., July 10, 2024 /PRNewswire/ -- Today WellCare of North Carolina (WellCare), a Medicaid health plan and subsidiary of Centene Corporation (NYSE: CNC) has received Health Equity Accreditation Status by the National Committee for Quality Assurance (NCQA). Originally mandated for completion by mid-year 2025, WellCare achieved this milestone in mid-year 2024, showcasing its strong commitment to health equity.
"Achieving the NCQA Health Equity Accreditation demonstrates our commitment to health equity and our aim to support health and wellbeing within our membership and their lived communities," said Plan President & CEO for WellCare of North Carolina, Troy Hildreth. "We are dedicated to cultivating a culture that supports our efforts to reduce health inequities and improve care quality for our diverse member population."
The NCQA Health Equity Accreditation gives healthcare organizations an actionable framework for improving health equity. This accreditation recognizes WellCare for its commitment to delivering high-quality, equitable healthcare to its members and its ongoing commitment to eliminating health disparities to support better health outcomes across the state. WellCare has proactively secured this accreditation a year ahead of the required timeline set by the North Carolina Department of Health and Human Services (NC DHHS). Health Equity Accreditation is awarded for three years and WellCare will continue to work toward renewing its accreditation status in the future.
NCQA is an independent, not-for-profit organization dedicated to improving healthcare quality. The NCQA Health Plan Accreditation shows members and providers that a health plan is well managed and delivers high-quality care and services, while demonstrating their commitment to advancing health equity.
About WellCare of North Carolina
Headquartered in Raleigh, WellCare of North Carolina provides government-sponsored managed care services to families, children, seniors, and individuals with complex needs primarily through Medicaid as one of the state's Medicaid Prepaid Health Plans (WellCare of North Carolina), Marketplace (WellCare of North Carolina by Celtic Insurance Company), Medicare Advantage (Wellcare), and Medicare Prescription Drug Plans (Wellcare). WellCare of North Carolina is a wholly owned subsidiary of Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives. For more information, visit www.WellCareNC.com.
About Centene Corporation
Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under- insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. The Company also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and value creation as well as the development of its people, systems and capabilities so that it can better serve its members, providers, local communities and government partners. Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, http://investors.centene.com.
Last Trade: | US$65.12 |
Daily Change: | 1.59 2.50 |
Daily Volume: | 3,473,641 |
Market Cap: | US$32.880B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load